Association Between Survival Benefits of Anticancer Drugs and Probability of US Food and Drug Administration Approval: A Systematic Review
OncologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Pharmaceutical medicine
- Publicado em
- 31 mar 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Association Between Survival Benefits of Anticancer Drugs and Probability of US Food and Drug Administration Approval: A Systematic Review
Koji Ishizuka, Shunsuke Ono
Descritores MeSH
- Neoplasms
- Drug Approval
- Antineoplastic Agents
- United States Food and Drug Administration
- Randomized Controlled Trials as Topic
- Clinical Trials, Phase III as Topic
- Humans
- United States
Veja também
Estudos relacionados
- Longitudinal changes in the relative toxicity of FDA-approved oncology therapeutics: evidence from paired initial and updated RCT reports
- Evolution of clinical benefit in cancer trials: comparing pivotal approval data with updated efficacy
- Pivotal studies of pharmacotherapies approved by the US FDA for cancer treatment: a meta-analysis
- Review of All Solid Tumor Drug Approvals From 2019 to 2024 by US Food and Drug Administration, European Medicines Agency, and Brazilian Health Regulatory Agency